Peptides
Tirzepatide Without Diabetes: What the Meta-Analysis Behind the Hype Actually Shows
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.